Idera Pharmaceuticals Announces Initiation of a Phase 2 Trial of IMO-8400 in Patients with Moderate to Severe Plaque Psoriasis "This Phase 2 trial of IMO-8400 will enable us to evaluate over a 12-week ...

The clinical stage biopharma said that it is selling 25 million shares of common stock for $2.00 each. In addition, the company also granted the underwriters of the deal the option to purchase an ...

HOUSTON—May 23, 2019—Idera, Inc. (“Idera” or “the Company”), parent company of global B2B software productivity brands, today announced it will receive a new minority investment from Partners Group, a ...

The biopharma announced a massive public stock offering. The financing will add net proceeds of $46.8 million. While that's a sizable amount and will prove useful in efforts to further develop its ...

EXTON, Pa., March 31, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today ...

Idera announced that the merger has been terminated after BioCryst's stockholders voted against the deal in a special meeting held on Tuesday, July 10, 2018. Idera's shareholders also held a special ...

Cambridge, Mass.-based Idera Pharmaceuticals and Bermuda-based Vivelix Pharmaceuticals entered into an exclusive license and collaboration agreement giving Vivelix the rights to develop and market IMO ...

Shares of Idera Pharmaceuticals (NASDAQ: IDRA) are down around 15% year to date. And that's a good thing, relatively speaking: The clinical-stage biotech's stock was down by more than 55% just a few ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to ...

Idera said on Monday that it has named Randy Jacops as CEO. Recently, Jacops worked as a venture partner at Valhalla Partners. Also, Josh Stephens has been hired as the company’s vice president of ...

New AI capabilities help DBAs move from performance visibility to performance resolution--turning slow queries into actionable index recommendations in minutes HOUSTON, March 19, 2026 /PRNewswire/ -- ...